The global pruritus therapeutics market has been gaining significant traction as chronic skin conditions become increasingly prevalent worldwide. In 2024, the market was valued at USD 9.08 billion, with projections to reach USD 9.48 billion in 2025 and further expand to USD 13.39 billion by 2032. This growth reflects a stable yet meaningful compound annual...

The global pruritus therapeutics market has been gaining significant traction as chronic skin conditions become increasingly prevalent worldwide. In 2024, the market was valued at USD 9.08 billion, with projections to reach USD 9.48 billion in 2025 and further expand to USD 13.39 billion by 2032. This growth reflects a stable yet meaningful compound annual...

The Pruritus Therapeutics Market is witnessing significant transformation, shaped by innovation, evolving consumer expectations, regulatory shifts, and global economic trends. Polaris Market Research’s latest report, Pruritus Therapeutics Market, offers a holistic view of the market. It examines the market’s structure, growth drivers, competitive landscape, and future...

Valued at USD 8.63 billion in 2024, the pruritus therapeutics market is projected to reach USD 8.97 billion in 2025 and USD 12.61 billion by 2034, growing at a CAGR of 5.50% during the forecast period 2025–2034. Major players include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb, Cara Therapeutics, GSK plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical...

According to a new report by Polaris Market Research, the global pruritus therapeutics market was valued at USD 8.97 billion in 2025 and is projected to reach USD 12.61 billion by 2034, expanding at a CAGR of 5.50% over the forecast period. Growth is underpinned by the rising prevalence of dermatological and systemic conditions causing chronic itching, expanding biologics...